The MedTech Funding Mandate (MTFM) is a NHS Long Term Plan commitment to get selected NICE-approved cost-saving devices, diagnostics and digital products to NHS patients more quickly. The policy launched on 1 April 2021. After the first year of the new policy, new guidance was published for 2022/23. Access the policy guidance here.

The policy supports devices, diagnostics or digital products that:

  • are effective and improve patient outcomes: demonstrated through positive NICE guidance;
  • are cost-saving within three years: NICE modelling demonstrates a net saving within three years of implementing the technology;
  • are affordable to the NHS: the budget impact should not exceed £20 million, in any of the first three years.


The policy defines a list of NICE-approved technologies that NHS commissioners and providers are mandated to agree local funding arrangements for through their existing allocations. This is to ensure healthcare providers across England enable equitable access to patients.

The MTFM policy is an NHS England initiative, delivered with the support of the 15 AHSNs who work closely with their local ICSs. Providers wishing to implement any of the supported technologies, can contact their regional AHSN for support.

The policy has three key objectives:

  • Ensure equity in healthcare provision is achieved by monitoring patient access to the supported technologies across the NHS in England
  • Direct the NHS to the medical technology innovations that are most effective and likely to give savings on investment.
  • Support the NHS to develop a sustainable approach to overcoming the financial barriers to adopting medical devices, diagnostics and digital products.


Technologies included in the 2022/23 policy:

The technologies included in the MTFM 2022/23 policy are categorised into the following two themes:

Benign prostatic hyperplasia (BPH) – a common condition in ageing men and others with a prostate (trans women, some non-binary and some intersex people). It is currently treated with the surgical procedure, transurethral resection of the prostate (TURP) which usually requires the patient to stay in hospital for 1 to 3 days. Four less invasive innovations allow patients with BPH to be treated as day cases.

Four technologies are an alternative treatment to transurethral resection of the prostate (TURP) for benign prostatic hyperplasia:

  • Greenlight XPS – uses a laser to reduce the size of an enlarged prostate. Find out more about Greenlight XPS in this short film.
  • Rezum – uses water vapour to destroy excess prostate tissue. Find out more about Rezum in this short film.
  • PLASMA System – uses electrodes to cut out prostate tissue. Find out more about PLASMA System in this short film.
  • UroLift – lifts and holds the enlarged prostate tissue away from the urethra, relieving the compression of this organ. Find out more about UroLift in this short film.


Improving the patient experience during procedures – using technology can provide alternatives to otherwise more invasive and costly procedures.

Three technologies are an alternative to more invasive procedures:

  • Spectra Optia – apheresis and cell collection platform for people with sickle cell disease who require automated red cell exchange. Find out more about Spectra Optia in this short film.
  • XprESS Multi Sinus Dilation System – a sterile, single-use device for treating chronic sinusitis with a dilating balloon. Find out more about XprESS in this short film.
  • Thopaz+ – a portable digital chest drain system which accurately monitors and records air leak and fluid drainage. Find out more about Thipaz+ in this short film.


Technologies receiving continued support from the 2021/22 policy are:

  1. Placental growth factor based testing (PlGF) – a blood test to rule out pre-eclampsia in pregnant women. Find out more about PlGF in this short film.
  2. SecurAcath – for securing percutaneous catheters. Find out more about SecurAcath in this short film.
  3. HeartFlow – creates a 3D model of a patient’s coronary arteries and assesses the extent and location of blockages. Find out more about HeartFlow in this short film.
  4. gammaCore – a handheld device which alleviates the symptoms of severe cluster headaches. Find out more about gammaCore in this short film.


Introducing the 22/23 MedTech Funding Mandate policy

Find out more about the MTFM in this series of short films recorded at a briefing in March 2022. You can access the whole playlist here.

Watch Matt Whitty, Director of Innovation, Research and Life Sciences (IRLS) and Chief Executive of AAC discuss the MTFM.

Watch Phil Jennings, Chief Executive of Innovation Agency and Chief Officer Lead at the AHSN Network for MTFM explain how AHSNs can help providers deliver the policy.

Watch Stuart Monk, National Programme Director for Rapid Uptake Products and MedTech Funding Mandate Programmes at the AHSN Network explain the AHSN role in the delivery of the MTFM.

Watch Sarah Tyers, MedTech Funding Mandate Policy Lead at the Innovation, Research and Life Sciences Group talk about how the national tariff system supports MTFM.

Watch Zinah Sorefan, Senior Analytical Manager at the Innovation, Research and Life Sciences Group discuss how we demonstrate adopter performance across the country.

Watch Gary Shield, Resource Impact Assessment Manager on the Strategy and Transformation Directorate at NICE discuss how to access resource impact assessment (RIA) templates and tools.

Watch Andrew Lane, Senior Category Tower Manager at NHS Supply Chain and project lead talk about the benefits of buying through NHS Supply Chain.

Watch Phil Corran, Research and Innovation Coordinator in the MTFM team address questions that have been submitted prior to the event.


Providers wishing to implement any of the supported technologies, please contact your regional AHSN.

For more information about the policy, contact the innovation team in the AAC via, including ‘MTFM’ in the subject line.